Regulatory issues
APhA's expert team consistently advocates to the Administration and federal agencies (HHS, CMS, FDA, CDC, NIH, DEA, FTC, and others) on issues of importance to pharmacy and pharmacists, including recognition of pharmacists as providers, payment reform, expansion of pharmacists’ patient care services, addressing the opioid crisis, health IT, telehealth, and other policies to improve public health.
Sweeping expansion of pharmacists’ scope of practice during COVID-19
APhA is pushing to make permanent the largest expansion of pharmacist authorities that were introduced as part of the pandemic response including allowing pharmacies to offer FDA-approved vaccines and therapeutics, point-of-care tests, and Medicare reimbursement for administration of COVID-19 vaccines at a rate nearly double the current rate, flexibility to compound medications in shortage for hospitalized patients, and flexible telehealth authorities. We’ve already helped increase the number of pharmacies participating in the Federal Retail Pharmacy Program for COVID-19 vaccines from 17,000 to nearly 40,000.